News

Fierce Pharma23h
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The Cardiology Advisor20h
Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
NJBIZ1d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
The Economist18h
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk Forges Multiple Partnerships To Sell Obesity Drug Wegovy At A Discount
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
pharmaphorum5d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...